Paul Sekhri

Biography

Paul Sekhri has more than 25 years’ experience in life sciences, having served in executive leadership positions at some of the most widely regarded pharmaceutical companies in the world. He is operating partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures, and is president and CEO of Lycera, an innovative biopharmaceutical company focused on treatments for autoimmune diseases and cancer. Prior he served as senior vice president, integrated care at Sanofi where he lead the creation of innovative solutions and business models to meet patient needs. Before Sanofi, Paul led global business development and was chief strategy officer at Teva. He also served as operating partner and head, biotech ops group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life sciences companies. He has held the roles of founder, president, and chief executive officer of Cerimon Pharmaceuticals; president and chief business officer of ARIAD Pharmaceuticals; and partner for healthcare investments of New Leaf Ventures. Paul spent four years at Novartis, where he developed the disease area strategy, and founded the early commercial development department. Paul has served as a director of numerous private and public company boards, including Nivalis Therapeutics, Pharming N.V., Enumeral Biomedical Holdings, Inc., KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions, and Tandem Diabetes, and as board advisor to IMS Health. Paul received his bachelor of science degree in zoology from the University of Maryland, College Park.

Research Interest

Pharmaceuticals